Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trevi Therapeutics ( (TRVI) ) just unveiled an update.
On June 2, 2025, Trevi Therapeutics announced the termination of its ATM Prospectus related to a sales agreement with Leerink Partners, initially dated August 15, 2023. This decision halts the sale of common stock under the agreement until a new prospectus is filed, although the agreement itself remains valid. As of March 31, 2025, Trevi had sold over 4.4 million shares for approximately $14.6 million in gross proceeds, highlighting its previous capital-raising efforts.
The most recent analyst rating on (TRVI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Trevi Therapeutics stock, see the TRVI Stock Forecast page.
Spark’s Take on TRVI Stock
According to Spark, TipRanks’ AI Analyst, TRVI is a Neutral.
Trevi Therapeutics shows promise with significant clinical progress and a strong cash position, essential for sustaining operations in a pre-revenue phase. However, ongoing financial losses and valuation risks temper the outlook. The stock’s technical indicators suggest strong momentum, but investors should be cautious due to potential volatility and financial risks inherent in early-stage biotechnology companies.
To see Spark’s full report on TRVI stock, click here.
More about Trevi Therapeutics
Trevi Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing therapies for serious neurologically mediated conditions.
Average Trading Volume: 2,319,792
Technical Sentiment Signal: Buy
Current Market Cap: $662.4M
For an in-depth examination of TRVI stock, go to TipRanks’ Stock Analysis page.